Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 8/20 | 0.76 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.76 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.69 |
| ▸ | OSBP | P22059 | 4/20 | 0.69 |
| ▸ | RORC | P51449 | 4/20 | 0.69 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.69 |
| ▸ | CRYAB | P02511 | 1/20 | 0.69 |
| ▸ | HMGCR | P04035 | 1/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.69 |
| ▸ | ITGAV | P06756 | 1/20 | 0.69 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.69 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.57 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24085650 | 1.00 | GRIN1 (0.76) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL8336467 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL6391972 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL6387555 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL6387062 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL8336472 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL6388729 | 0.88 | RORC (0.74) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL14770941 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL14771158 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2BNR1H3OSBP | |
| SCHEMBL19506256 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2BNR1H3OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114224-A1 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | SAGE THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3919502-A1 | 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA RELATED CONDITIONS | Sage Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210147468-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3481846-B1 | 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA RELATED CONDITIONS | SAGE THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10781231-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781231-B2 | Oxysterols and methods of use thereof | HSD3B1, CYP17A1, HSD17B7 | GRIN1 1672/4885GRIN2A 2309/4885GRIN2B 1699/4885 |
| US-20210147468-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | HSD3B1, CYP17A1, HSD17B7 | GRIN1 1673/4885GRIN2A 2346/4885GRIN2B 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.